These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 15962407)

  • 1. What ails the FDA?
    Jenny-Avital ER
    N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
    [No Abstract]   [Full Text] [Related]  

  • 2. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 3. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH
    Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract]   [Full Text] [Related]  

  • 4. The drive to reform the FDA gains momentum.
    Gatty B
    Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
    [No Abstract]   [Full Text] [Related]  

  • 5. Who would approve new drugs if there were no FDA?
    Gatty B
    Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
    [No Abstract]   [Full Text] [Related]  

  • 6. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 8. Perspectives. Approval process a moving target in FDA reform hearings.
    Rhein R
    Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
    [No Abstract]   [Full Text] [Related]  

  • 9. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 10. The big gap at the FDA.
    Stipp D
    Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA embraces risk-management approach.
    Fox JL
    Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 13. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 14. What ails the FDA?
    Cohen FJ
    N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962406
    [No Abstract]   [Full Text] [Related]  

  • 15. What ails the FDA?
    Gorelick KJ
    N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814
    [No Abstract]   [Full Text] [Related]  

  • 16. Confronting the future of the FDA.
    Serafini MW
    Natl J (Wash); 1996 Dec; 28(50):2704-5. PubMed ID: 10163877
    [No Abstract]   [Full Text] [Related]  

  • 17. Should you let the FDA decide what drugs you pay for?
    Dutton G
    Bus Health; 1996 Oct; 14(10):65, 69-70, 73. PubMed ID: 10161492
    [No Abstract]   [Full Text] [Related]  

  • 18. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 19. The special treatment.
    Osborne R
    Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
    [No Abstract]   [Full Text] [Related]  

  • 20. Getting SMART (submission management and review tracking) drug review in the computer age.
    Flieger K
    FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.